International Women's Day—how can I help?

Orkin, Chloe; Apea, Vanessa

doi:10.1016/s2352-3018(22)00060-1

Cited by 5 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 , 4 , 5 , 6 , 7 , 8 , 9 Furthermore, most epidemiological surveillance datasets have not distinguished between cis and trans women, thereby prohibiting a detailed description and characterisation of any differences in these two subpopulations, 21 , 22 which are generally under-represented and under-reported in HIV and sexual health research. 23 Although women account for a minority of infections reported in the current monkeypox outbreak (<5%), 20 we anticipate that this might change as the outbreak evolves. It is important to collect and report on these infections to investigate sex and gender specificities in disease presentation.…”

Section: Discussionmentioning

confidence: 96%

“… 26 65% of trans women and 53% of cis women and non-binary individuals without known HIV were tested for HIV at presentation for monkeypox, suggesting that the strong association between a monkeypox virus diagnosis and HIV infection has, regrettably, still not translated into systematic HIV screening for all individuals with monkeypox virus infection. 23 More concurrent STIs were documented in trans women (21%) than in cis women and in non-binary individuals (7%). However, it is notable that in some countries, screening for Chlamydia trachomatis and Neisseria gonorrhoeae infections were not routinely done because of laboratory restrictions relating to biosafety.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series

Thornhill¹,

Palich²,

Ghosn³

et al. 2022

The Lancet

Self Cite

102

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series

Thornhill¹,

Palich²,

Ghosn³

et al. 2022

The Lancet

Self Cite

102

View full text Add to dashboard Cite

“…15 Fifty-seven per cent of heterosexuals people living with HIV in the UK are of Black African heritage 16 and 14% of men who have sex with men living with HIV are from racially minoritised backgrounds. 16 Achieving equity of care for women and racially minoritised people living with HIV requires a bold and inclusive approach to research 17 which is why we have developed this protocol for implementing LAIs in multiple settings, with a focus on under-represented populations. The Implementing Long-Acting Novel Antiretrovirals (ILANA) study aims at exploring study participants' experiences and perceptions of the LA injectable CAB+RPV and its facilitation in the NHS.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

Study protocol: the ILANA study – exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK – a qualitative multiphase longitudinal study design

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionCabotegravir and rilpivirine (CAB+RPV long-acting (LA)) is recommended as a treatment for HIV-1 allowing people living with HIV to receive 2 monthly injectable treatment, rather than daily pills. Providing injectable therapy in a system designed to provide and manage study participants on oral treatments poses logistical challenges namely how resources are used to accommodate patient preference within constrained health economies with capacity limitations. In this pragmatic multicentre study, we aim to understand the implementation of CAB-RPV-LA administration in two settings via mixed methods to explore perspectives of participants and the clinical team delivering CAB+RPV LA.Methods and analysisWomen, racially minoritised people and older people are chronically under-represented in HIV clinical trials so the ILANA trial has set recruitment caps to ensure recruitment of 50% women, 50% ethnically diverse people and 30% over 50 years of age to include a more representative study population. Using a mixed-methods approach, the primary objective is to identify and evaluate the critical implementation strategies for CAB+RPV LA in both hospital and community settings. Secondary objectives include evaluating feasibility and acceptability of CAB+RPV LA administration at UK clinics and community settings from the perspective of HIV care providers, nurses and representatives at community sites, evaluating barriers to implementation, the utility of implementation strategies and adherence.Ethics and disseminationEthical approval has been obtained from the Health Research Authority Research Ethics Committee (REC reference: 22/PR/0318). The dissemination strategy has been formulated with the SHARE Collaborative Community Advisory Board to maximise the impact of this work on clinical care and policy. This strategy draws on and leverages existing resources within the participating organisations, such as their academic infrastructure, professional relationships and community networks. The strategy will leverage the Public Engagement Team and press office to support dissemination of findings.Trial registration numberNCT05294159.

show abstract

“…Achieving equity of care for women and racially-minoritised people living with HIV requires a bold and inclusive approach to research (17) which is why we have developed this protocol for implementing LAIs in multiple settings, with a focus on under-represented populations. The ILANA study aims at exploring patients' experiences and perceptions of the long-acting injectable CAB+RPV and its facilitation in the NHS.…”

Section: Introductionmentioning

confidence: 99%

The ILANA study: a paradigm shift in ensuring equity of clinical implementation in HIV research

Farooq

Apea

Kasadha

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction Cabotegravir and Rilpivirine (CAB+RPV-LA) is recommended as a treatment for HIV-1 allowing people living with HIV to receive two-monthly injectable treatment, rather than daily pills. Providing injectable therapy in a system designed to provide and manage patients on oral treatments poses logistical challenges namely how resources are used to accommodate patient preference within constrained health economies with capacity limitations. In this pragmatic multi-centre study, we aim to understand the implementation of CAB-RPV-LA administration in two settings via mixed methods to explore perspectives of participants and the clinical team delivering CAB+RPV-LA. Methods and Analysis Women, racially minoritised people and older people are chronically under-represented in HIV clinical trials so the ILANA trial has set recruitment caps to ensure recruitment of 50% women, 50% ethnically-diverse people and 30% over 50 years of age to include a more representative study population. Utilising a mixed-methods approach, the primary objective is to identify and evaluate the critical implementation strategies for CAB+RPV-LA in both hospital and community settings. Secondary objectives include evaluating feasibility and acceptability of CAB+RPV-LA administration at UK clinics and community settings from the perspective of HIV care providers, nurses, and representatives at community sites, evaluating barriers to implementation, the utility of implementation strategies, and adherence. Ethics and Dissemination Ethical approval has been obtained from the Health Research Authority Research Ethics Committee (REC reference: 22/PR/0318). The dissemination strategy has been formulated with the SHARE Collaborative Community Advisory Board in order to maximise the impact of this work on clinical care and policy. This strategy draws upon and leverages existing resources within the participating organisations, such as their academic infrastructure, professional relationships and community networks fully. The strategy will particularly harness the Public Engagement Team and press office to support dissemination of findings. Registration Number ClinicalTrials.gov Identifier:NCT05294159

show abstract

International Women's Day—how can I help?

Cited by 5 publications

References 6 publications

Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series

Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series

Study protocol: the ILANA study – exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK – a qualitative multiphase longitudinal study design

The ILANA study: a paradigm shift in ensuring equity of clinical implementation in HIV research

Contact Info

Product

Resources

About